|Category||Life Sciences and Bio Technology|
|Keywords||Antibodies, NK cells|
|Current development stage||TRL4 – POC & Safety of candidate drug formulation is demonstrated in defined animal model|
Natural killer (NK) cells are innate effector lymphocytes that efficiently kill tumor cells without prior stimulation. NK are crucial first responders to tumor transformation and viral, bacterial, or fungal infections. They are also involved in autoimmune diseases such as Type 1 and 2 Diabetes.
NKp46 is an important activating receptor of NK cells. It plays an important role in the identification and elimination of various NK cell targets. NKp46’s function was established in various autoimmune diseases. In Type 1 Diabetes NKp46 was shown to kill beta cells and in Type 2 Diabetes it was shown to affect macrophages polarization via the secretion of IFN. NKp46 expression is elevated in NK cells found in the synovial fluids of RA patients. Finally, expression of NKp46 is induced on NK and some T cell leukemia.
The researchers developed a Novel NKp46 antibody for preventing and/or treating malignant and autoimmune diseases.
- The antibody induces NKp46 internalization and degradation
- The antibody significantly affects NKp46 activity against NKp46-dependent targets demonstrating decreased killing of tumor cells, virally infected cells and pancreatic beta cells.
- Toxin-conjugated antibody kills NKp46 positive tumors
The finding uncovers that the human NKp46 receptor and its mouse homologue NCR-1 specifically recognize both human and murine pancreatic β-cells. By using NKp46 knockout mice and the LDST model, it was shown that the development of diabetes is impaired in the absence of NKp46. It was demonstrated in vitro that the killing of β-cells derived from NOD mice is also NKp46 dependent. Thus, NKp46 is a significant determinant in the progression from insulitis to diabetes. Binding of the antibody induce NKp46 internalization. Useful for the killing of tumors expression NKp46.
- Therapeutic drug for the treatment of NKp46-dependent autoimmune diseases, such as, Type 1 Diabetes and RA, and NK cell related malignancies.
- Prevent the development of Type1 Diabetes and the life-long treatment of insulin. There is no equivalent type of drug to treatment of Type 1 Diabetes today which addresses the disease itself and not the symptoms (i.e insulin).